Sysmex America and Advanced Instruments announced a partnership that will broaden the Sysmex portfolio with Advanced Instruments’ automated “GloCyte” cell counter system. The technology provides an unprecedented detection level for automated cerebrospinal fluid (CSF) cell counts to labs across the Americas.
CSF is collected from patients when it is critical to physicians’ ability to diagnose leukemia, hemorrhaging, malignancies, infections, and other conditions, which may involve the central nervous system.
Advanced Instruments’ patented GloCyte system uses a unique combination of fluorescence, microscopy with digital image analysis, highly specific reagents and an intelligent counting algorithm to provide extremely precise, reliable, timely, and linear counts down to zero for both red blood cell (RBC) and total nucleated cell (TNC) in cerebrospinal fluid in adult and pediatric patients.
Prior to the introduction of the automated GloCyte system, the standard method of counting RBC and TNC was a labor-intensive, manual process using a Neubauer Hemocytometer counting chamber, and could only be performed by specialized laboratory staff.
“The addition of GloCyte makes our portfolio of diagnostic analyzers even more versatile, scalable and customizable to the unique needs of the many laboratories and physicians who depend on them to provide patients with the very best in healthcare,” said Andy Hay, chief operating officer of Sysmex America. “While diagnostic technology like our XN-3100 and XN-9100 provide highly accurate and reliable results for an array of health conditions, for laboratories testing CSF, adding GloCyte is a solution that provides accurate cell counts at clinically relevant low levels while offering maximum efficiency and minimum workflow disruption.”
Under the agreement, Sysmex America, Inc. will be the exclusive distributor of GloCyte in the U.S., Canada and Latin America.
“Our two companies share a commitment to the highest levels of accuracy and reliability in diagnostic testing and customer service,” said Byron Selman, president and chief executive officer of Advanced Instruments. “For laboratories that conduct CSF testing, the addition of GloCyte will provide the lowest level of detection for an automated cell counter at one cell per microliter with faster turnaround times.”
Business as usual for GloCyte and Sysmex customers
Advanced Instruments and Sysmex America will carefully implement a seamless transition for customers during the next few months, ensuring that laboratories continue to enjoy the high level of service and support they receive today. Additional information will be provided directly to GloCyte customers in the coming weeks.
Until then, GloCyte customers should operate on a “business as usual” basis and continue to work with Advanced Instruments.